Maximus review

Maximus publishes unusually thorough safety documentation. Its safety page is dated (last updated June 2, 2026), carries a version history, is organized protocol by protocol, and volunteers the facts a marketing page usually leaves out: that enclomiphene is not FDA-approved as a standalone drug, that all current sermorelin is compounded because the approved product was discontinued, and that a telehealth clinician cannot examine you. Every product has a real month-to-month price beside cheaper multi-month plans. Two things weigh against it: the FDA sent Maximus a warning letter in June 2026, shown on this page, and its headline results figures come from the company's own uncontrolled studies.

A men's-health telehealth company, Maximus Health, Inc., founded in 2020 with S. Cameron Sepah, PhD, as founder and CEO. It sells testosterone in three exogenous routes (injectable, cream and oral), a separate enclomiphene line, a sermorelin growth-hormone peptide program, compounded GLP-1 microdosing and branded GLP-1s (Zepbound, Wegovy pens and tablets, Foundayo, Ozempic and Mounjaro), plus blood-flow, hair and lab-testing products. A separate peptides page asks visitors to vote on future "stacks," some including tesamorelin, that are not yet for sale. Despite its enclomiphene reputation, it sells real exogenous testosterone across all three routes.

Fully online with no in-person option, and asynchronous-first: complete an evaluation and intake, order an at-home lab test, have a licensed doctor finalize the prescription based on results, then monitor and adjust with 24/7 messaging. There is no mandatory scheduled video visit. Lab work is a real gate for testosterone, required to confirm eligibility, guide dosing and monitor markers over time, with an upload path if you have bloodwork from the last six months covering total testosterone, SHBG or free testosterone, LH, PSA and hematocrit. Pricing, side-effect information and FAQs are public with no signup gate, and the site advertises no membership fee and free priority shipping. State availability is published per product: sermorelin is available everywhere except Alabama, and the branded GLP-1s everywhere except Alabama, Mississippi and Louisiana. In California, sermorelin comes in a smaller vial at a lower dose. Maximus says it partners exclusively with LegitScript-certified US pharmacies, a claim about the pharmacies rather than about itself. No prescribing clinician is named; the peptide page quotes "our Medical Director" without a name.

A ladder where the month-to-month tier is real. Injectable testosterone and testosterone cream are each $199.99 a month month-to-month, $149.99 on three months and $99.99 on six. Oral testosterone is $249.99, $199.99 and $149.99. Enclomiphene is $199.99 month-to-month, $149.99 on three months and $99.99 only on twelve. Sermorelin is $299.99 month-to-month, $274.99 on a two-month plan and $199.99 on six, for a 10 mL, 20 mg vial that Maximus calls a 28-day supply at 1 mg five days a week. Because a no-commitment price exists on every product, that is the figure to compare. Three cautions. A banner offers 50% off the first month only to new customers buying a six-month plan (twelve months for enclomiphene), a promotion layered on a commitment. Injectable testosterone and enclomiphene both advertise "starting at $99.99," but on six- and twelve-month plans respectively. And the sermorelin page says both "less than $6/day" and "under $9/day"; at $199.99 for a 28-day vial it is about $7.14 a day, and at the month-to-month price about $10.71. Every product page notes that pricing varies by dosage, plan length and state.

Compounded; not FDA-approved — and Maximus discloses this with unusual specificity. Its safety page states per product which items are compounded and which are approved, volunteers that enclomiphene is not FDA-approved as a standalone drug, and explains that sermorelin was previously approved as Geref but has been discontinued, so all current sermorelin is compounded. It cites FDA class labeling and links manufacturer prescribing information for the branded GLP-1s. Its testosterone is real exogenous hormone dispensed from compounding pharmacies, with oral and cream formulations compounded and not FDA-approved as finished products; the injectable is made in MCT oil rather than seed oils. The efficacy figures quoted on its testosterone pages and in its whitepapers come from the company's own self-published, uncontrolled studies rather than peer-reviewed controlled trials, so read them as company-reported. On the evidence, sermorelin acts on the growth-hormone axis with thin long-term human outcome data. Testosterone replacement has a large randomized safety base and still requires monitoring. Individual results vary.